Formex, LLC, a provider of small molecule formulation and clinical trial manufacturing, has launched its dedicated suites for R&D and cGMP production capabilities of cytotoxic and potent pharmaceuticals.   “The addition of our cytotoxic and potent handling suites deepens Formex’s ability to handle a broader range of active pharmaceutical ingredients (APIs). Specialized handling of cytotoxic and potent compounds is a strategic complement to our existing technologies for bioavailab...